Cooperation

• ADC Drug GQ1010, Co-Developed by Tyligand Bioscience and GeneQuantum Healthcare, was licensed to Pyridmid Biosciences, with upfront and milestone payment up to $ 1 billion
• Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER
• Tyligand Bioscience Aquired ONA-XR (Onapristone sustained relese) right of development and commercialization in Greater China
• Tyligand Bioscience Receives U.S. FDA Orphan Drug Designation for TSN084 for the Treatment of Acute Myeloid Leukemia